About
Provirex (PROVIREX Genome Editing Therapies GmbH) develops a recombinase-based genome editing therapy (Brec1) designed to excise integrated HIV proviral DNA from infected cells. The company is advancing into clinical development and operates ATMP manufacturing S3 biosafety cleanrooms in Hamburg.
Explore Provirex's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.